Literature DB >> 11599625

Deep vein thrombosis in patients admitted for exacerbation of chronic obstructive pulmonary disease.

W Y Pek1, A Johan, S Stan, P Lee, C B Chee, Y T Wang.   

Abstract

INTRODUCTION: There is a lack of data on the prevalence of deep vein thrombosis and pulmonary embolism in patients admitted to hospital for exacerbation of chronic obstructive pulmonary disease. Studies have found that most pulmonary embolism originate from deep vein thrombosis in the lower limbs, thus the prevalence of deep vein thrombosis may give an accurate reflection of the prevalence of pulmonary embolism. The aim of our study was to determine the prevalence of deep vein thrombosis in these patients, using duplex ultrasound of the lower limbs as the screening tool.
METHODS: Thirty-three male patients admitted to the general ward for exacerbation of chronic obstructive pulmonary disease were screened for presence of deep vein thrombosis of the lower limbs using duplex ultrasound scan. RESULT: No patient in this study was found to have deep vein thrombosis of the lower limbs.
CONCLUSIONS: The prevalence of deep vein thrombosis in local patients admitted for exacerbation of chronic obstructive pulmonary disease is likely to be low. We do not recommend the use of duplex ultrasound to screen for deep vein thrombosis in this group of patients.

Entities:  

Mesh:

Year:  2001        PMID: 11599625

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  2 in total

1.  Prevalence of Pulmonary Embolism and Deep Venous Thromboembolism in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.

Authors:  Weihong Han; Minghang Wang; Yang Xie; Huanrong Ruan; Hulei Zhao; Jiansheng Li
Journal:  Front Cardiovasc Med       Date:  2022-03-09

2.  The Incidence of Deep Vein Thrombosis in Asian Patients With Chronic Obstructive Pulmonary Disease.

Authors:  Chung-Yu Chen; Kuang-Ming Liao
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.